Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Studies

Vesugen

KED, Lys-Glu-Asp tripeptide

Quick Stats
Studies 19
Trials 1
Overview Studies Clinical Trials
Score 3
2014 pubmed

[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].

Kitachev. K V KV; Sazonov. A B AB; Kozlov. K L KL; Petrov. K Iu KIu; Sliusarev. A S AS; Khavinson. V Kh VKh

View Original Source

Key Findings

  • Vezugen (a vasoactive tripeptide) was administered as a single therapy to men with vascular‑related erectile dysfunction.
  • Blood flow measurements in the main penile artery showed a significant increase after treatment.
  • Clinical symptoms of erectile dysfunction improved alongside the objective blood‑flow improvements.

Practical Outcomes

  • The study suggests Vezugen may help restore penile blood flow and improve erectile function in older men with atherosclerosis‑related ED. However, the trial provides no details on dosing, safety, or long‑term effects, so biohackers should treat it as preliminary evidence and await more robust data before incorporating it into personal protocols.

Summary

A small study gave the peptide Vezugen to 41 older men with erectile dysfunction caused by poor blood flow. After treatment, blood flow in the main penile artery improved, and the men reported better erectile function.

Abstract

Atherosclerosis is a leading cause of obliterating diseases of the arteries in 80-90% of cases. The main pathogenetic mechanism is endothelial dysfunction, leading to hypertension, diabetes, congestive heart failure. The desire of modern society to improve the quality of life increases interest of human health in general and sexual health in particular, because the erectile function is an important factor in the quality of life, which makes us look for more effective methods of diagnosis, treatment and rehabilitation. The objective of the study was to assess the effectiveness of vasoactive tripeptide Vezugen in patients with vasculogenic erectile dysfunction as manifestation of atherosclerosis. Treatment results of erectile dysfunction in 41 patients were studied. A comparative analysis of clinical and instrumental parameters of blood flow in the main penile arteries before and after monotherapy was undertaken. The results show that the blood flow through the main artery of the penis after Vezugen treatment significantly improved both clinical and by objective indicators.

Study Information

Provider

pubmed

Year

2014